EGFR and non-small cell lung carcinoma: The mutations that have shown a response to first- and second-generation EGFR TKIs previously described are generally rare in SNSCC (as well as in NSCLC), and therefore the majority of EGFR Ex20ins patients are unlikely to benefit from these therapies.